← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,559	+36	+2%	$106B
2	2 Danaher DHR $158B	1,404	+28	+2%	$82.3B
3	3 Novartis NVS $279B	1,094	-40	-4%	$23.5B
4	4 Illumina ILMN $41B	885	+8	+0.9%	$50B
5	5 Agilent Technologies A $49.1B	698	-34	-5%	$20.2B
6	6 Regeneron Pharmaceuticals REGN $80.1B	658	-61	-8%	$23.1B
7	7 Revvity RVTY $17B	435	+15	+4%	$10.3B
8	8 Charles River Laboratories CRL $14.4B	405	-4	-1%	$6.64B
9	9 Ionis Pharmaceuticals IONS $7.1B	396	+3	+0.8%	$8.14B
10	10 Sarepta Therapeutics SRPT $1.78B	365	-7	-2%	$10.9B
11	11 Alnylam Pharmaceuticals ALNY $30B	290	-1	-0.3%	$7.7B
12	12 DELISTED CATALENT, INC. CTLT	288	+5	+2%	$8.33B
13	13 DELISTED bluebird bio BLUE	273	-15	-5%	$7.92B
14	14 Qiagen QGEN $9.41B	262	0	0%	$5.79B
15	15 Bruker BRKR $8.47B	258	+9	+4%	$5.3B
16	16 Azenta AZTA $1.63B	257	+15	+6%	$2.85B
17	17 Myriad Genetics MYGN $397M	235	-27	-10%	$2.14B
18	18 Guardant Health GH $21.9B	217	+67	+45%	$6.57B
19	19 Arrowhead Research ARWR $8.25B	212	+37	+21%	$1.82B
20	20 Veracyte VCYT $3.5B	195	+46	+31%	$1.37B
21	21 Editas Medicine EDIT $349M	193	-8	-4%	$984M
22	22 Regenxbio RGNX $454M	186	-25	-12%	$1.51B
23	23 DELISTED SANGAMO THERAPEUTICS INC SGMO	185	-2	-1%	$862M
24	24 CareDx CDNA $3.35B	182	0	0%	$1.41B
25	25 CRISPR Therapeutics CRSP $4.86B	181	+11	+6%	$1.29B